Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly

BACKGROUND Aspirin is a well‐established therapy for the secondary prevention of cardiovascular events. However, its role in the primary prevention of cardiovascular disease is unclear, especially in older persons, who have an increased risk. METHODS From 2010 through 2014, we enrolled community‐dwelling men and women in Australia and the United States who were 70 years of age or older (or ≥65 years of age among blacks and Hispanics in the United States) and did not have cardiovascular disease, dementia, or disability. Participants were randomly assigned to receive 100 mg of enteric‐coated aspirin or placebo. The primary end point was a composite of death, dementia, or persistent physical disability; results for this end point are reported in another article in the Journal. Secondary end points included major hemorrhage and cardiovascular disease (defined as fatal coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal stroke, or hospitalization for heart failure). RESULTS Of the 19,114 persons who were enrolled in the trial, 9525 were assigned to receive aspirin and 9589 to receive placebo. After a median of 4.7 years of follow‐up, the rate of cardiovascular disease was 10.7 events per 1000 person‐years in the aspirin group and 11.3 events per 1000 person‐years in the placebo group (hazard ratio, 0.95; 95% confidence interval [CI], 0.83 to 1.08). The rate of major hemorrhage was 8.6 events per 1000 person‐years and 6.2 events per 1000 person‐years, respectively (hazard ratio, 1.38; 95% CI, 1.18 to 1.62; P<0.001). CONCLUSIONS The use of low‐dose aspirin as a primary prevention strategy in older adults resulted in a significantly higher risk of major hemorrhage and did not result in a significantly lower risk of cardiovascular disease than placebo. (Funded by the National Institute on Aging and others; ASPREE ClinicalTrials.gov number, NCT01038583.)

[1]  Elsdon Storey,et al.  Effect of Aspirin on All‐Cause Mortality in the Healthy Elderly , 2018, The New England journal of medicine.

[2]  Suzanne G. Orchard,et al.  Effect of Aspirin on Disability‐free Survival in the Healthy Elderly , 2018, The New England journal of medicine.

[3]  A. Squizzato,et al.  Aspirin Plus Clopidogrel vs Aspirin Alone for Preventing Cardiovascular Events Among Patients at High Risk for Cardiovascular Events. , 2018, JAMA.

[4]  J. McNeil,et al.  Development of a standardized definition for clinically significant bleeding in the ASPirin in Reducing Events in the Elderly (ASPREE) trial , 2018, Contemporary clinical trials communications.

[5]  C. Reid,et al.  The aspirin in reducing events in the elderly trial: Statistical analysis plan , 2018, International journal of stroke : official journal of the International Stroke Society.

[6]  P. Rothwell,et al.  Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study , 2017, The Lancet.

[7]  Lawrence J. Fine,et al.  Decline in Cardiovascular Mortality: Possible Causes and Implications , 2017, Circulation research.

[8]  T. Morimoto,et al.  Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial , 2016, Circulation.

[9]  D. Rockey,et al.  RE: Risks of Bleeding Recurrence and Cardiovascular Events With Continued Aspirin Use After Lower Gastrointestinal Hemorrhage. , 2017, Gastroenterology.

[10]  Shankun Liu,et al.  The Benefit and Safety of Aspirin for Primary Prevention of Ischemic Stroke: A Meta-Analysis of Randomized Trials , 2016, Front. Pharmacol..

[11]  Yuling Hong,et al.  Heart Disease and Cancer Deaths — Trends and Projections in the United States, 1969–2020 , 2016, Preventing chronic disease.

[12]  D. Angiolillo,et al.  Aspirin for Primary Cardiovascular Risk Prevention and Beyond in Diabetes Mellitus , 2016, Circulation.

[13]  S. Malayala,et al.  Compliance with USPSTF recommendations on aspirin for prevention of cardiovascular disease in men , 2016, International journal of clinical practice.

[14]  J. Manson,et al.  Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease: Advances in Diagnosis and Treatment. , 2016, JAMA internal medicine.

[15]  E. Whitlock,et al.  Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force , 2016, Annals of Internal Medicine.

[16]  Kirsten Bibbins-Domingo,et al.  Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. , 2016, Annals of internal medicine.

[17]  E. Whitlock,et al.  Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services Task Force , 2016, Annals of Internal Medicine.

[18]  K. Shimada,et al.  Aspirin for Stroke Prevention in Elderly Patients With Vascular Risk Factors: Japanese Primary Prevention Project , 2016, Stroke.

[19]  J. Bosch,et al.  Updated Meta-Analysis of Aspirin in Primary Prevention of Cardiovascular Disease. , 2016, The American journal of medicine.

[20]  G. Lip,et al.  Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. , 2015, European heart journal.

[21]  C. Dillon,et al.  Preventive Aspirin and other Antiplatelet Medication Use among U.S. Adults Aged ≥40 Years: Data from the National Health and Nutrition Examination Survey, 2011–2012 , 2015, Public health reports.

[22]  K. Shimada,et al.  Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. , 2014, JAMA.

[23]  S. Rezkalla,et al.  The Role of Aspirin in the Prevention of Cardiovascular Disease , 2014, Clinical Medicine & Research.

[24]  F. Hu,et al.  Aspirin for Primary Prevention of Cardiovascular Events: Meta-Analysis of Randomized Controlled Trials and Subgroup Analysis by Sex and Diabetes Status , 2014, PloS one.

[25]  D. Whellan,et al.  Aspirin for Cardioprotection and Strategies to Improve Patient Adherence , 2014, Postgraduate medicine.

[26]  C. Reid,et al.  Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial. , 2013, Contemporary clinical trials.

[27]  G. Triadafilopoulos,et al.  Alarmingly poor adherence to low-dose aspirin: a large population-based study , 2013 .

[28]  L. Moon,et al.  Latest statistics on cardiovascular disease in Australia , 2013, Clinical and experimental pharmacology & physiology.

[29]  M. Nelson,et al.  Primary prevention of cardiovascular disease: new guidelines, technologies and therapies , 2013, The Medical journal of Australia.

[30]  J. Eikelboom,et al.  The aspirin controversy in primary prevention , 2012, Current opinion in cardiology.

[31]  J. McNeil,et al.  Aspirin for Primary Prevention of Cardiovascular Events in the Elderly , 2012, Drugs & Aging.

[32]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[33]  G. Tognoni,et al.  Association of aspirin use with major bleeding in patients with and without diabetes. , 2012, JAMA.

[34]  H. Putter,et al.  Competing risks in epidemiology: possibilities and pitfalls. , 2012, International journal of epidemiology.

[35]  M. O’Donnell,et al.  Effect of aspirin on mortality in the primary prevention of cardiovascular disease. , 2011, The American journal of medicine.

[36]  J. Berger,et al.  Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials. , 2011, American heart journal.

[37]  G. Howard,et al.  Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. , 2011, The American journal of cardiology.

[38]  P. Sandercock,et al.  Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. , 2010, JAMA.

[39]  A. Newman,et al.  The burden of cardiovascular disease in the elderly: morbidity, mortality, and costs. , 2009, Clinics in geriatric medicine.

[40]  R. Collins,et al.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. , 2009, Lancet.

[41]  R. Collins,et al.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials , 2009, The Lancet.

[42]  G. Boysen,et al.  European Guidelines on Cardiovascular Disease Prevention , 2009, International journal of stroke : official journal of the International Stroke Society.

[43]  S. Yusuf,et al.  Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. , 2008, European heart journal.

[44]  Biomed Programme Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials , 2009 .

[45]  T. Morimoto,et al.  Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients With Type 2 Diabetes , 2012 .

[46]  P. Macfarlane,et al.  The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease , 2008, BMJ : British Medical Journal.

[47]  C. Lau,et al.  Incidence and predictors of upper gastrointestinal bleeding in patients receiving low-dose aspirin for secondary prevention of cardiovascular events in patients with coronary artery disease. , 2006, World journal of gastroenterology.

[48]  A. Mokdad,et al.  Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System. , 2006, American journal of preventive medicine.

[49]  P. Gorelick,et al.  Risk of Hemorrhagic Stroke With Aspirin Use: An Update , 2005, Stroke.

[50]  T. Vos,et al.  Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged ≥70 , 2005, BMJ : British Medical Journal.

[51]  Weigh risks and benefits of aspirin in the secondary or primary prevention of cardiovascular events in elderly individuals , 2004 .

[52]  A. Leizorovicz,et al.  Aspirin for the Prevention of Cardiovascular Events in the Elderly , 2003, Drugs & aging.

[53]  J. McNeil,et al.  Rationale for a Trial of Low-Dose Aspirin for the Primary Prevention of Major Adverse Cardiovascular Events and Vascular Dementia in the Elderly , 2003, Drugs & aging.

[54]  M. Rosenberg,et al.  Review: aspirin reduces CAD events in people with no history of cardiovascular disease, but it increases gastrointestinal bleeding , 2002, ACP journal club.

[55]  Enoxaparin sodium and aspirin: bleeding events after renal transplant , 2002 .

[56]  R. Gryglewski,et al.  Unusual effects of aspirin on ticlopidine induced thrombolysis , 2000, Thorax.

[57]  J S Alpert,et al.  Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. , 2000, Journal of the American College of Cardiology.

[58]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[59]  V. Fuster,et al.  Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. , 1997, Circulation.

[60]  P. Armstrong Clopidogrel was more efficacious than aspirin in preventing major cardiovascular events. , 1997, Evidence-based cardiovascular medicine.

[61]  Lippincott Williams Wilkins,et al.  Stroke--1989. Recommendations on stroke prevention, diagnosis, and therapy. Report of the WHO Task Force on Stroke and other Cerebrovascular Disorders. , 1989, Stroke.

[62]  Final report on the aspirin component of the ongoing Physicians' Health Study. , 1989, The New England journal of medicine.

[63]  D. Kim,et al.  Aspirin (I) , 1978 .